The professionalism of Halsin towards investor and public relations is far beyond the norm, in particular your ‘can do’ service attitude."

OUR WORK - Case Studies

 

Background:

Alnylam is a leader the field of RNAi therapeutics. The company was founded on the back of specific technology and intellectual property, and at the same time as several other companies in the field. To enable it to stay ahead of the field, Alnylam decided to merge with Ribopharma in Germany, a company with strong complimentary patents and technology.

Objectives:

  • Position Alnylam as the global leader in RNAi therapeutics with acquisition of private German competitor
  • Highlight the enormous therapeutic impact that RNAi may have on human health
  • Manage multi-language communications, particularly in English and German
  • Support the private financing that coincided with the merger transaction

Method:

To meet Alnylam’s objectives, the media strategy needed to have an impact both globally and in the local German market. This challenge was met by approaching the Wall Street Journal with an English exclusive, Handelsblatt with a German semi-exclusive and local newspapers in Kulmbach with a semi-exclusive. This first tier of outreach was supported by general outreach to biotech reporters throughout Europe, financial and trade press.

Results:

  • Exclusive article in Wall Street Journal appearing in US, European and Asian versions
  • Exclusive article in Handelsblatt
  • Extensive German coverage, including Financinal Times Deutschland and local Kulmbach press
  • Significant pick up in other European countries including UK, France, Belgium, Spain, Greece
  • Interest by publications with planned RNAi features at a future date
  • Continued interest in the company by European press